Skip to content

Apriori Bio is working to create a world where humanity is protected against viral threats. The company’s pioneering approach centers on its unique technology platform, Octavia™, which allows Apriori to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Latest News from Apriori Bio